Sanofi Won’t Go Above $70/Share for Genzyme

August 25, 2010

175

Sanofi-Aventis SA is not willing to pay more than $70 per share for U.S. biotech Genzyme Corp. and may look at alternative targets, Bloomberg reported on Wednesday, citing sources familiar with the matter.

*For more on this story, read the full Reuters article.

Want more from the best local business newspaper in the country?

Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!

Would you like to subscribe to Orange County Business Journal?

One-Year for Only $99

Unlimited access to OCBJ.com
Daily OCBJ Updates delivered via email each weekday morning
Journal issues in both print and digital format
The annual Book of Lists: industry of Orange County's leading companies
Special Features: OC's Wealthiest, OC 500, Best Places to Work, Charity Event Guide, and many more!

Home Refinancing Demand Up, Rates Hit New Lows

Toll Brothers Posts Profit for Q3

staff-author

Sanofi Won’t Go Above $70/Share for Genzyme

Want more from the best local business newspaper in the country?

Would you like to subscribe to Orange County Business Journal?

Featured Articles

OC Leader Board: The Future of Private Business

Hightower to Buy Newport Beach’s Bahnsen Group

Five Point Holdings Post $5M Loss in Q1

Related Articles

OC Leader Board: The Future of Private Business

Hightower to Buy Newport Beach’s Bahnsen Group

Five Point Holdings Post $5M Loss in Q1

Morinaga Builds $130 Million Hi-Chew Factory

Alteryx Launches AI Insights Agent on Google Cloud Marketplace

Advertise With Us

About Us

Subscriber Links

Other Journals